Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573170 · ClinicalTrials.gov registry record · Phase 3
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
A Phase 3 study of Migraine Disorders and Migraine, Acute, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
- 20
- Study locations
NCT00573170 is a Phase 3 study of Migraine Disorders and Migraine, Acute that has completed, run by GlaxoSmithKline. The registered enrollment target is 375 participants, above the 297-participant average among 21 other Migraine Disorders trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT00573170, a Phase 3 study of Migraine Disorders and Migraine, Acute, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine (Studies 1 and 2 of 2)
Conditions Studied
Interventions
- DRUG placebo
- DRUG TREXIMET®
- DRUG Butalbital-containing Combination Medications (BCM)
Study Locations (20)
California
- GSK Investigational Site - Anaheim
- GSk Investigational Site - Anaheim
- GSK Investigational Site - Garden Grove
- GSK Investigational Site - Irvine
- GSK Investigational Site - Newport Beach
- GSK Investigational Site - Northridge
- GSK Investigational Site - Riverside
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Francisco
- GSK Investigational Site - Santa Monica
- GSK Investigational Site - Sherman Oaks
Arizona
- GSK Investigational Site - Chandler
- GSK Investigational Site - Gilbert
- GSK Investigational Site - Litchfield Park
- GSK Investigational Site - Mesa
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tempe
Arkansas
- GSK Investigational Site - Little Rock
- GSK Investigational Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00573170
The ClinicalTrials.gov registry entry for NCT00573170 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 297-participant average among 21 other Migraine Disorders trials with a reported enrollment target (26% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Migraine Disorders appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00573170 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00573170 about?
NCT00573170 is a clinical study titled "TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults". Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the M...
What is the current status of trial NCT00573170?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2008-02. Estimated completion is 2009-08.
What conditions does trial NCT00573170 study?
This clinical trial studies the following conditions: Migraine Disorders, Migraine, Acute.
What interventions are being tested in trial NCT00573170?
The interventions under investigation include: placebo (DRUG), TREXIMET® (DRUG), Butalbital-containing Combination Medications (BCM) (DRUG).
Who is sponsoring clinical trial NCT00573170?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00573170 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Study of MAP0004 in Adult Migraineurs
COMPLETED · Phase 3
-
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
COMPLETED · Phase 3
-
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
COMPLETED · Phase 3
-
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
COMPLETED · Phase 3
-
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
COMPLETED · Phase 3
-
Migraine Manager (R01)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.